...
首页> 外文期刊>Journal of Medical Virology >Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis
【24h】

Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis

机译:抗病毒治疗与肝炎三角洲影响的移民患者队列中的聚乙二醇干扰素和临床结果:回顾性分析

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic hepatitis delta (CHD) is the most severe chronic hepatitis, with no satisfactory treatment options and severe clinical outcomes. This infection is frequent in the migrant subjects from endemic areas, especially from Africa and East-Europe. The pegylated (PEG)-interferon a (IFN) is limited by side effects and poor response. In this retrospective analysis, we reported our experience of treatment with PEG-IFN in a cohort of immigrant patients affected by CHD. We evaluated the virological responses are as follows: complete response (CR; clearance of hepatitis B surface antigen [HBsAg] and hepatitis D virus [HDV]-RNA), partial response (PR; HBsAg clearance with HDV-RNA+), and null response (NR; HBsAg and HDV-RNA+). Clinical outcomes were clinical stabilization, disease progression, hepatic decompensation, hepatocellular carcinoma (HCC), death, and liver transplantation. Forty-six patients were included. At the end of treatment (ET), 11 patients gained a CR (23.9%), 10 were PR (21.7%), and 16 were NR (34.8%). After 1 year, 10 remained with CR (21.7%), after 2 years, 9 (19.5%), and at 3 years, 8 (17.4%). Relapse rate was 2.2%, 4.4%, and 6.5% at year 1, 2, and 3, respectively. Favorable factors were CR at the ET (odds ratio [OR] = 4.559, 95% confidence interval [CI]: 2.219-7.116; P = 0.003), PEG-IFN course greater than 1 (OR = 1.240, 95% CI: 0.998-4.839; P = 0.012), prolonged treatment (OR = 1.276, 95% CI: 0.816-3.108; P = 0.018), quantitative hepatitis B surface antigen (qHBsAg) decline at 12 weeks greater than 0.5 log IU/mL (OR = 4.816, 95% CI: 2.190-8.194; P < 0.001). The unfavorable factors were cirrhosis (OR = 3.122, 95% CI: 1.466-4.190; P = 0.012), active hepatitis B virus (OR = 2.334, 95% CI: 1.788-3.992; P = 0.018), NR at ET (OR = 6.998, 95% CI: 5.987-11.404; P < 0001). Treatment of CHD is limited by poor virological response; is NR unfavorable outcomes were unavoidable. No other treatment options were available.
机译:慢性肝炎三角洲(CHD)是最严重的慢性肝炎,没有令人满意的治疗方案和严重的临床结果。这种感染在流行区域的移民受试者中经常出现,特别是来自非洲和东欧。聚乙二醇化(PEG) - interferona(IFN)受副作用和响应差的限制。在此回顾性分析中,我们向受CHD影响的移民患者队列中的PEG-IFN治疗经验。我们评估了病毒学反应如下:完全反应(Cr;乙型肝炎表面抗原[HBsAg]和丙型肝炎病毒[HDV] -RNA的清除,部分反应(PR; HBsAg与HDV-RNA +的间隙)和空响应(NR; HBsAg和HDV-RNA +)。临床结果是临床稳定,疾病进展,肝脏失代偿,肝细胞癌(HCC),死亡和肝移植。包括四十六名患者。在治疗结束时(ET),11名患者获得Cr(23.9%),10例为Pr(21.7%),16例NR(34.8%)。 1年后,10岁以下,2年后,9名(19.5%),3年,8(17.4%)。复发率分别为2.2%,4.4%和6.5%,分别为1,2和3。有利因素是ET(差距[或] = 4.559,95%置信区间[CI]:2.219-7.116; P = 0.003),大于1(或= 1.240,95%CI:0.998的PEG-IFN疗程-4.839; p = 0.012),延长治疗(或= 1.276,95%ci:0.816-3.108; p = 0.018),定量乙型肝炎表面抗原(qhbsag)下降12周大于0.5 log iu / ml(或= 4.816,95%CI:2.190-8.194; P <0.001)。不利因素是肝硬化(或= 3.122,95%CI:1.466-4.190; p = 0.012),活性乙型肝炎病毒(或= 2.334,95%CI:1.788-3.992; p = 0.018),nr处(或= 6.998,95%CI:5.987-11.404; P <0001)。 CHD的治疗受病毒学反应差的限制;是不利的结果是不可避免的。没有其他治疗选择可用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号